Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 12th, 2021

Organ on demand technology leads to new CVD treatments


Brenda Ogle, PhD
Brenda Ogle, PhD

The relatively new technology of 3D printing has already taken hold in the worlds of manufacturing, education and construction, and it is continuing to make inroads in medicine as well.

“Organ on Demand: 3D Printing for CVD,” 4:30-5:30 p.m. EST, will take a closer look at the progress made in using 3D printing for heart and lung vessels to develop both research models and alternative transplant solutions.

Brenda Ogle, PhD, professor and head of the Department of Biomedical Engineering at the University of Minnesota in Minneapolis-St. Paul, said the technology has developed to such a point that it can be used to generate centimeter-scale muscle. This in turn has allowed for a new approach to generating a living, human cardiac muscle pump.Optimization of an extracellular matrix-based bioink for printing geometrically complex cardiac structures. A, Bioink formulations delineated in the Table were combined with human induced pluripotent cells (hiPSCs) and pipetted into wells to form gels.Optimization of an extracellular matrix-based bioink for printing geometrically complex cardiac structures. A, Bioink formulations delineated in the Table were combined with human induced pluripotent cells (hiPSCs) and pipetted into wells to form gels.

“The pump can be used to impose and study changes in volumetric pressure dynamics with health and disease,” she said. “In addition, it serves as a prelude to a therapeutic tissue graft capable of compensating for the decreased function of failing hearts.”

Dr. Ogle’s presentation, “In Situ Expansion, Differentiation and Electromechanical Coupling of Human Cardiac Muscle in a 3D Bioprinted, Chambered Organoid,” will take a closer look at this technology and how it could impact the treatment of cardiovascular disease going forward.

“This advance moves the field one step closer to a cardiac graft that does not depend on a matched donor organ,” she said. “The primary learning objective of this presentation is to understand the interplay between the extracellular matrix scaffold and cardiac cell types in the context of engineered tissues.”

In addition to Dr. Ogle, the session will explore updates on the first full-size, 3D bioprinted human heart by Adam Feinberg, PhD, Carnegie Mellon University, and 3D bioprinting of pre-vascularized tissue constructs with complex microarchitecture by Shaochen Chen, BS, University of California. 

Visit Scientific Sessions Conference Coverage for more articles.

Image used with permission: Kupfer et al. Circ Res. 2020;127:207–224. doi: CIRCRESAHA.119.316155. © 2020 American Heart Association, Inc. 

Interesting Stories
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
More Content
Getty Images 1180201381
Daily Coverage
Join the Scientific Sessions 2022 Scavenger Hunt
Aug 15th, 2022
Live Meeting Image
AHA21
Member Connect
Dec 13th, 2021
P104 Steven Botts Image
AHA21
Members Connect: ERG Governs Chromatin Accessibility in Aortic Endothelial Cells
Dec 13th, 2021
Pres Address Lloyd Jones2
AHA21
Watch: #AHA21 recap and look ahead
Nov 22nd, 2021
Getty Images 1301907602
AHA21
Mark your calendar for #AHA22
Nov 19th, 2021
Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
Nov 19th, 2021
Lbs02 Group Blood Patel
AHA21
Update on local and global hypertension science
Nov 19th, 2021
Getty Images 1219980553 61849bc953192
AHA21
Read all about #AHA21 in your daily coverage
Nov 16th, 2021
(from left to right): Brahmajee K. Nallamothu, MD, MPH, FAHA, Rhoda Au, PhD, Seth Martin, MD, MHS, FAHA, and Andrea Beaton, MD, FAHA
AHA21
QCOR at Sessions: mHealth strategies could help treat CVD around the world
Nov 15th, 2021
(from left to right, top to bottom rows): Corey E. Ventetuolo, MD, MS, Magdi Yacoub, OM, FRS, Karen Joynt Maddox, MD, MPH, FAHA, Gregory Lewis, MD, Marco Guazzi, MD, PhD, FAHA, Ana Macumbi, MD, PhD, FESC, Mark T. Gladwin, MD, FAHA, and William Bain, MD
AHA21
The shifting profile of cardiopulmonary COVID-19 survivors
Nov 15th, 2021
(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
AHA21
Late-Breaking Science: New information in cardiac disease
Nov 15th, 2021
(from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA
AHA21
The latest science in heart failure
Nov 15th, 2021